COVID-19 antibodies can last up to 500 days after infection

Adults infected with COVID-19 develop circulating antibodies that last for nearly 500 days, according to a new study led by researchers atUTHealth School of Public Health.

The findings were published inThe Journal of Infectious Diseases.

beplay苹果手机能用吗研究人员检查了来自德克萨斯州57,000多名志愿者的数据，这些数据已有20岁以上，他们参加了德克萨斯州Cares调查，该调查始于2020年10月，目的是评估Covid-19的抗体状态，随着时间的流逝。得克萨斯州的孩子。

“这些结果是有前途的,因为我们现在有一个good estimate of how long antibodies last after a COVID-19 infection,” said Michael Swartz, PhD, associate professor and vice chair of biostatistics at UTHealth School of Public Health and corresponding author on the study. “Our research shows that the level of antibodies in those previously infected increases for the first 100 days post-infection and then gradually declines over the next 500 days and beyond.”

beplay苹果手机能用吗研究人员从2020年10月1日至2021年9月17日使用血液抽样样品。大多数志愿者自我报告了2020年10月之前自我报告的19 covid-19。结果根据年龄，体重指数，人与人之间的结果有所不同（体重指数（BMI），吸烟或吸烟以及感染的严重程度；但是，所有志愿者均显示抗体相似。

The results of this study are just another step in understanding the virus’s impact, and although antibodies after infection can last for almost a year and half, Swartz says it’s important to understand that being vaccinated against the virus offers the best protection against infection, reinfection, or hospitalization.

“Vaccines are a great source of protection. We know that the rates of reinfection or hospitalization after being vaccinated are a lot lower than not being vaccinated, especially against other variants like we saw with Delta and Omicron. So, if you haven’t been vaccinated, now is the time to do it,” Swartz said.

Previous researchout of Texas CARES found children previously infected with COVID-19 had circulating antibodies that lasted for at least seven months.

The Texas CARES program is still ongoing. To learn more about how to get involved, visithttps://sph.uth.edu/projects/texascares/.

Additional UTHealth Houston authors include: Eric Boerwinkle, PhD; Stacia M. DeSantis, PhD; Ashraf Yaseen, PhD; Frances A. Brito, MS; Melissa A. Valerio-Shewmaker, PhD, MPH; Sarah E. Messiah, PhD, MPH; Luis G. Leon-Novelo, PhD; Harold W. Kohl III, PhD, MSPH; Cesar L. Pinzon-Gomez, MD; Tianyao Hao, MS; Shiming Zhang, MS; Yashar Talebi, MS; Joy Yoo, BS; Jessica R. Ross, BS; Michael O. Gonzalez, MS; Leqing Wu, PhD; and Steven H. Kelder, PhD, MPH. Other authors include Mark Silberman, MD, and Samantha Tuzo, BS, with Clinical Pathology Laboratories; Jennifer A. Shuford, MD, MPH, and Stephen J. Pont, MD, MPH, with the Texas Department of State Health Services; and David Lakey, MD, with The University of Texas System.

德克萨斯州护理的资金由德克萨斯州卫生服务部（合同＃HHS000866600001）提供。

媒体询问：713-500-3030